Chapter

Benzimidazoles: From Antiproliferative to Multitargeted Anticancer Agents

Yousef Najajreh

Abstract

Benzimidazole derivatives are known to act against a range of biological targets and thus gained clinical applications in a wide spectrum of diseases. Few examples of multitargeted benzimidazole derivatives that were reported during the last decade will be described in this chapter. Multitargeting agents for serving the polypharmacology approach to combat shortcomings of the main one-drug-one target main dogma will be briefly explored. In that context, the multitargeting benzimidazole derivatives gain a special attention. This includes discovery (hit-to-lead), structure-activity relationship (SAR), and binding mode of at least one lead (or hit) in each group. Special attention will be given to two structures dovitinib and AT9283 that are reported to exhibit potent in vitro and in vivo activities against a group of kinases and non-kinase target (as shown recently for dovitinib).

Keywords: benzimidazole, selective, cytotoxic, inhibitor, multitargeting, multikinase, polypharmacology, antiproliferative, quinolinone, carbamate, quinolinone, pyrazole, urea, aniline, anilinobenzimidazolylypyrimidine, chloroacetamide, amidine, binding, mode

1. Introduction

1.1 Antiproliferative action of benzimidazoles

Benzimidazole, a heterocyclic moiety comprising six-membered benzene ring fused with five-membered imidazole ring, containing molecules, was known for its ability to induce antiproliferative effects (named as antineoplastic, anticancer, or antitumor agents). Numerous structures were reported as effective inhibitors of cell growth and division, thus acting as antiviral, antibacterial, antifungal, anthelmintic (or antihelminthics), and anticancer agents. Over the years, several published scripts have reviewed the synthetic approaches, medicinal chemistry, SAR, bioactivities, and preclinical and clinical studies of such “gifted” fragment [1–8].

1.2 Benzimidazoles act on numerous biological targets

A wide range of activities and medical situations benzimidazole containing compounds have been used for. That includes antihypertensive [9–12], anti-inflammatory [13–15], antibacterial [16–18], antiviral [19–21], antifungal [22–24], antihelmintic [25–28], anticancer [29–32], antiulcer [33–35], antioxidant [36–38], and
psychoactive drugs [39]. And proton pump inhibitors [8, 33], anticoagulants [40, 41], immunomodulators [42], hormone modulators [43, 44], antidepressants [45], lipid level modulators [46–49], and antiidiabetics [50–52] are partial list of therapeutic effects of benzimidazole containing comprising compounds. Benzimidazole derivatives exert their actions by interacting with vital biological targets including β-tubulin [52–55], DNA minor groove [56–58], serotonin receptors (5-hydroxytryptamine receptors; 5-HT) [59–62], histamine receptors 4 (H4H) [63], dopamine receptor 2 (D2R) [64], chemokine receptor (CXCXR3) [65], interleukin 2-inducible T-cell kinase (ITK) [66], lymphocyte tyrosine kinase (Lck) [67], phosphatidylinositol 3-kinase (PI3K) [68], activated protein kinase (MEK1) [69, 70], anaplastic lymphoma kinase (ALK) [71], polo-like kinase 1 (PLK1) [72, 73], breakpoint cluster region-Abelson kinase (BCR-Abi) [74], casein kinase 2 (CK2) [75], telangiectasia and Rad3-related protein kinase (ATR) [76], tyrosine kinase receptors [fibroblast growth factor receptors (FGFR-1/FGFR-2/FGFR-3)], vascular endothelial growth factor receptor (VEGFR-1/VEGFR-2/VEGFR-3), platelet-derived growth factor receptor (PDGFR-α/PDGFR-β), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase 3 (FLT3) [77], poly(ADP-ribose)polymerase-1 (PARP-1) [78–82], dihydroorotate dehydrogenase (DHODH) [83], topoisomerase 1 (TOP01) [84], DNA and RNA polymerases [85–89], histone deacetylase 2 (HDAC2) and sirtuin [3, 90], antagonism of angiotensin 1 [2], neuropeptide Y binding [91], inhibition of proton pumps [8], DNA intercalating agents [92], inhibition of cyclin-dependent kinases (CDK) activity [93–96], activation of the p53 protein [97], etc. to mention part of the asserted cellular targets.

1.3 Scope: benzimidazoles as emerging multitargeting agents

The profound success in bringing into clinical application several kinase inhibitors as anticancer drugs made “kinase targeting” a central branch of targetable biomolecules during the past two decades. Nevertheless, the emerging of resistant tumors kinase-directed therapeutics and adverse side effects turned such promising “targeted therapeutics” into challenging field. In addition, it was noticed that lack of response to kinase inhibitors is accompanied by changes in signaling network composition through adaptive kinase reprogramming. Such reprogramming is believed to allow the tumor to escape effects of the drug and manifest resistance. In contrast to the “one-drug-one-target” approach, the “bitopic, that is, two drugs acting on one target” or the “dual, that is, one drug acting on two targets,” “polypharmacology” which refers to a novel paradigm that purposes at “simultaneous modulation of more than two biological targets by a single drug” has been emerging as strategy to improve the efficacy and durability of clinical responses to therapies. In cancer treatment, polypharmacology is a result of the ability of “one drug” to simultaneously inhibit multiple cancer-driving targets. However, discovering inhibitors with an appropriate multitarget profile is a challenging task that necessitates a systemic deeper investigation accompanied by major clinical developments. Therefore, a strategy is required to identify single polypharmacological agents with the ability to target multiple cancer-promoting or sustaining pathways that does not necessarily rely on inhibiting multiple kinases [98]. As a matter of fact, high ratio (~30%) of the FDA-approved kinome-targeting drugs were reported be multitargeted ones [99]. Actually, the first kinase inhibitor imatinib was approved as multitarget agent in a later stage (in addition to its primary target BCR-Abi, it inhibits stem cell factor receptor (c-KIT) and platelet-derived growth factor receptors A and B (PDGFRα and PDGFRβ) tyrosine kinases and human quinone reductase 2
Figure 1.
Multitargeting anticancer agents. (a) Multitargeting cytotoxic benzimidazole-based structures. 3-Benzimidazol-2-ylhydroquinolin-2-one based dovitinib [TKI258, CHIR258; (1)], N-cyclopropyl-
N’-[3-[[4-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]Urea [AT9283 (2)], 2-anilino-4-(benzimidazol-2-yl)pyrimidine based [2-anilino-4-(benzimidazol-2-yl)pyrimidine 2-methoxy-5-[[4-(1-methyl-1H-benzimidazol-2-yl)pyrimidin-2-yl]amino]phenol (3)], α-haloacetamidebenzimidazole-
based [2-chloro-N-(2-(p-tolyl)-1H-benzo[d]imidazol-5-yl)acetamide (4)], and amidine-benzimidazole based [2-(4-((1-benzyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-5-(4,5-dihydro-1H-imidazol-2-yl)-1H-benzo[d]imidazole (5)]; (b) FDA-approved multitargeting anticancer agents [sorafenib (6), regorafenib (7) sunitinib (8), axitinib (9), and lenvatinib mesylate (10) and pazopanib (11)].
Chemistry and Applications of Benzimidazole and its Derivatives

(NQO2)). Thus the question of how efficacious are selective and specific one-drug-one-target-approved agents in treating advanced and metastatic cancer is still under evaluation [100–102].

This chapter will concisely provide a deeper insight into the benzimidazole-containing structures that exhibit action on multiple cellular targets. Special focus will be drawn to the identification and discovery, the structural activity relationship, proposed binding and interaction, and mechanism of action of each group of compounds. Detailed synthetic procedures and preclinical and clinical studies are out of scope of the current chapter. The focus of this chapter will be on groups of compounds that had been unveiled as concurrently antagonizing multiple targets. Instead, this chapter will focus on five groups of compounds reported to possess cytotoxic activities by acting on multiple (see Figure 1a) compounds (1, 2, 3, 4, and 5) holding the potential to be administered as “polytherapies.”

2. Benzimidazole scaffold for multitargeting of cancer

Multitargeting agent is defined as “a single chemical entity exerting action as a result of direct interactions on multiple biomolecular targets” [103]. Such agents can be beneficial in overcoming single (or dual)-targeting limitations including compromised effectiveness, severe side effects, emergence of resistant target mutants, and target non-related mutations. In addition, the efficacy of single-molecular-targeted FDA-approved agents in treating brutal and mortal cancers (breast, colorectal lung, pancreatic, and prostate) is limited. Most tumors escape from the inhibition of any single chemotherapeutic agent, and thus one possible therapeutic strategy could be in (1) administering cocktails of highly selective inhibitors (combinational therapy) or (2) development of multitarget inhibitors that act on inhibiting concurrently multiple validated target in cancer cell initiating a concerted molecular response, leading to cell death. Multitargeting chemotherapeutics hold the potential of exhibiting synergistic or at least additive effects when compared to single-targeted ones. It is believed that advances in signaling cascades, networks and crosstalk, chemo- and bioinformatics, detailed three-dimensional structural information of target proteins, computational chemistry tools, proteomics, etc. will allow for designing novel multitarget inhibitors.

It has been realized that molecular targeted therapeutics are facing acquired resistance. Multitargeting approach is gaining increased attention especially when combating resistant cancer cells. Accumulated evidence showed that drug treatment aggravates “selective pressure” of evolutionary force exerted on tumor cells that leads to resistance.

Benzimidazole fragment is reported to be an integral part of multitargeted inhibitors. Such inhibitors challenge the dominant paradigm in drug discovery which deemed to design and develop bioactive agent with maximum selectivity and specificity to individual drug target. Such compounds hold the hope for a new avenue of combating disease cases that could not be cured with one inhibitor acting on single target such as cancer [104, 105].

2.1 Benzimidazolylquinolinone: a scaffold for targeting multiple biomolecules

2.1.1 Discovery of dovitinib (TKI258, CHIR258)

Dovitinib [(TKI258, CHIR258); 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one (1)] was first designed and synthesized as vascular endothelial growth factor receptor (FEGFR) inhibitor in the
context of developing targeted antiangiogenic treatments [106]. The compound was later reported as a multitargeted kinase inhibitor (by [107]) following the realization that its potent inhibitory effects on cancer cells are associated with action on other multiple key players in oncogenesis, development, and proliferation of cancer [107].

The commercially available 3-benzimidazol-2-ylhydroquinolin-2-one scaffold [benzimidazolyquinolinone for short from now on, Figure 2 (13)] was identified using high-throughput screening (HTS) method and reported by Renhowe et al. (Novartis) as a potent (IC\textsubscript{50} values < 0.1 μM) reversible ATP competitive inhibitor of VEGFR-2, FGFR-1, and PDGFRβ [106]. Due to desirable properties as low-molecular-weight compound exhibiting submicromolar activity, (12) was considered a good hit to start with. To overcome the undesirable physicochemical properties of (13) (low aqueous solubility), further optimization was needed that ended up with a drug-like compound (1). Determining the key structural features required for potent kinase inhibition, molecular modeling was employed. The assumption was that in quinolinone portion, both NH at position 1 and the carbonyl group, together with benzimidazole NH, form a donor-acceptor-donor motif that would most probably bind to the hinge region of the RTKs and should be preserved.

To test this hypothesis, a systematic study was conducted through which hydrogen bond donors were masked by methyl group (CH\textsubscript{3}-) as shown in Figure 3 (13a–c) and 14a and 14b. These changes led to significant loss in the potency against all three receptor tyrosine kinases (VEGFR-2, FGFR-1, and PDGFRβ RTKs). The dimethylated analogue (Figure 3, 14b) showed no kinase activity at a concentration as high as 25 μM. Interestingly, it was noticed that monomethylation seemed to affect the kinase selectivity profile as well. Introduction of a methyl on the benzimidazole NH (13b) had a more dramatic effect on VEGFR-2 affinity than the methylation at NH in position 1 of the hydroquinolin-2-one (13a). This underlines the importance

**Figure 2.** Benzimidazolquinolinone-based multitargeting scaffold. (a) The basic skeleton of dovitinib (TKI258, CHIR258), 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one (12) with the two fragments quinolinone (blue) and benzimidazole (red) is indicated, (b) structures of commercially available starting “hit” (13) identified using HTS, and the “lead” approved as a multitargeting drug dovitinib (1).

**Figure 3.** Assessing the effect of the HBD and HBA on the activity of derivative of 3-benzimidazol-2-ylhydroquinolin-2-one. Methylated analogues of (13 and 14). The monomethylation caused a significant drop in the potency toward RTKs, while dimethylation aborted the RTKs’ activity [106].
of preventing the hydrogen bond donor (HBD). An opposite effect was noticed for FGFR-1, which indicates that despite the high homology of the two ATP-binding sites in the tow targets, selectivity opportunities still exist that are likely due to small changes in the shape of binding site. Such change in the shape can influence the accessibility of alternate binding poses of the monomethylated ligands (13a–13b and 14a in Figure 1) [106].

2.1.1.1 Structure–activity relationship (SAR)

The scaffold (13) was annotated by four rings (A–D). Modifications were introduced in a systemic manner. Once the basic structural components needed for affinity to targets of interest were understood, a study of the structure–activity relationship around the periphery of central 3-benzimidazol-2-ylhydroquinolin-2-one (13) scaffold was undertaken. Besides electrophilicity, nucleophilicity, bulkiness, steric hindrance, HBD versus HBA, and basicity, C4 of ring A was used for incorporation of moieties that might impart favorable physicochemical properties.

**SAR of ring B (C4):** While removal of the hydroxyl group reduced the activity, its replacement with amine improved significantly affinity to RTK and also cell potency [EC50 of 0.078 μM (NH2 > OH > H)], suggesting an importance of the HBD at C4 of the hydroquinolin-2-one fragment. Thus, incorporation of larger substituents on the C4-NH of the hydroquinolin-2-one was explored and found to be tolerated (see compounds 15b and 15c, Figure 4). Not only substantial improvement in the solubility was attained when the substituents carried an additional basic nitrogen were introduced to this position, it was noticed that this position modulates the selectivity profile of this class of compounds. It was reported that both derivatives (12a) and (12b) exhibited enhanced potency against PDGFR than VEGFR-1 (3000-fold) and FGFR (>1500-fold). Large basic amines like aminoquinuclidine potentiate the derivative (15d) against CHK-1 and GSK-3.

![Figure 4. Summary of structure–activity relationship (SAR) of 3-benzimidazol-2-ylhydroquinolin-2-one (1) [106].](image-url)
In conclusion, substitution at C4 position was revealed as critical to the activity of the benzimidazolylhydroquinolinone scaffold; however for RTK inhibitor program, the NH₂ group was the optimal substituent at C4 as it avoided inhibition of these additional serine threonine kinases, which could complicate the pharmacological application of these agents.

**SAR of ring D:** The overall structure–activity relationship (SAR) is summarized in Figure 4. Medicinal chemistry efforts were concluded in the selection of compound (1) as a candidate for further development. The compound (1) displayed exceedingly potent inhibitory effect when assessed against receptor protein kinases VEGFR-2, FGFR-1 and FGFR-3, PDGFRβ, VEGFR-1, VEGFR-2 and VEGFR-3, c-KIT, CSF-1R, and FLT-3 with IC₅₀ values between 3 and 27 nM. Such activity is translated into antiproliferative action on cells that are VEGF-, FGF-, SCF-, CSF-, or PDGF-driven. Mechanistically, it was also indicated that VEGF-mediated ERK phosphorylation was dipped in endothelial cells treated with (1).

In summary, dovitinib (1), an antineoplastic benzimidazolylquinolinone derivative, inhibits multiple growth factor receptor tyrosine kinases important for tumor angiogenesis and tumor growth. Dovitinib is well established as type III–V receptor tyrosine kinase (RTK) inhibitor. Though it potently inhibits fibroblast growth factor receptors (FGFR-1/FGFR-2/FGFR-3), the compound also inhibits vascular endothelial growth factor receptor (VEGFR-1/VEGFR-2/VEGFR-3), platelet-derived growth factor receptor (PDGFRα/β), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase 3 (FLT3), and colony-stimulating factor receptor 1 (CSF1R) emphasizing the nonspecific action of the drug [108]. The orally bioavailable lactate salt of (1) strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death. The activation of the abovementioned RTK in singularity or together is associated with cell proliferation and survival in all cancer cell types.

Dovitinib (TKI258, 1) is a highly potent, novel multitargeting receptor tyrosine kinase inhibitor with IC₅₀ of 1, 2, 10, 8, 27, and 36 nM for FLT3, c-KIT, VEGFR-1/VEGFR-2/VEGFR-3, PDGFRβ, and CSFR-1, respectively. Due to its inhibitory effect of VEGFR1/VEGFR2, the compound displayed both antitumor and antiangiogenic activities in vivo.

Trudel and colleagues reported that in addition to inhibiting the abovementioned TRKs (types II, IV, V), (1) potently inhibits wild-type (WT) FGFR3, F384L-FGFR3 (IC₅₀ = 25 nM), and FGFR3 mutants (IC₅₀ = 70–90 nM for the various mutations) driven by B9 cells [107]. Additionally, same group reported that (1) inhibited the proliferation of multiple myeloma (MM) cells. When assessing its antiproliferative effect against U266 and 8226 cells, (1) displayed a potent inhibitory effect (IC₅₀ ~ 90 nM) against KMS11 (FGFR3-Y373C), OPM2 (FGFR3-K650E) cells and IC₅₀ ~ 550 nM KMS18 (FGFR3-G384D) [109]. (1) Exhibited exceedingly potent antiproliferative effect against acute myelogenous leukemia (AML) cells MV4;11 (mutant FLT3-ITD) compared to AML RS4;11 (FLT3 WT) cells [EC₅₀ = 13 nmol/L and EC₅₀ = 315 nmol/L for MV4;11 and RS4;11, respectively, i.e., (~24-fold decrease in potency for FLT3 WT cells)]. Such results indicated that (1) exhibited far more potent activity against cells that are dependent on constitutively active FLT3-ITD. A similar conclusion was affirmed by Heise et al. by the notion that (CHIR258, 1) inhibited the proliferation of MOLM13 and MOLM14 that are FLT3-ITD mutant cells with EC₅₀ ~ 6 nmol/L similar to the ones with MV4;11 [109].

Besides the potent action of (1) against a wide range of RTK, its inhibitors’ effect ion fibroblast growth factor receptors in a variety of tumor xenograft models in athymic mice, including acute myeloid leukemia, multiple myeloma, and colon- and prostate-derived models was promising.
Recent studies reported the comparative activities of dovitinib against 16 colorectal cancer (CRC) cell lines (among them, 10 were KRAS or BRAF mutants). Results showed the affectivity of the drug in inhibiting the proliferation of majority of the cell lines excluding the ones harboring KRAS or BRAF mutants. However, when assessing the efficacy of the drug in vivo, it reduced the tumor growth in vivo regardless of the KRAS and BRAF mutation status. The drug exerted significant reduction of the xenograft size of both resistant cell lines (KRAS mutant LoVo cells but not in BRAF mutant HT-29) but without a detectable effect in the resistant mutant cell BRAF mutant HT-29 in vitro on s. Such results were explained by the multitarget action of the drug in which by acting on FGFR and FGFR together with VEGFR has been able to interfere with resistance mechanisms emerging from the synergistic interaction between the various signaling cascades in promoting neo-vascularization that is believed to be one resistance factor in renal cell carcinoma or pancreatic cancer [110, 111].

Dovitinib was selected to proceed ahead for preclinical and clinical trials. Several clinical trials have been conducted, and others are also underway with the drug and alone or in combination with several chemotherapeutic agents [112–118].

2.1.2 Binding mode of dovitinib (CHIR258, 1) to FGFR-1

Based on FGFR-1 crystal structure (PDB 2FGI) in conjunction with the information received from the X-ray structure of (1) with CHK1, a homology model for (1) complexed with VEGFR2 was constructed [106]. The model was helpful in guiding for the important interactions of (1) with active site. It was concluded that (1) participated in three hydrogen bonds to the hinge domain (Glu917 and Cys919). In addition A-ring makes a VDW interaction with the hydrophobic gatekeeper Val916 and was engaged in an S-H/π interaction with Cys1045. Leu840, Val848 (both in the P-loop and ceiling of the purine pocket), Ala866 (ceiling of the purine pocket), Val899 (floor of the purine pocket), Phe918 (part of the hinge), Lys920, Gly922 (both in the lower hinge region), and Leu1035 (floor of the purine pocket) took part in hydrophobic interaction with (1). In the following studies, the X-ray structures of (1) complexed with native and with mutant FGFR1 and with FGFR4 were reported [119–122].

2.1.2.1 Going beyond kinases

Although dovitinib binds to several kinases at nanomolar concentrations, recent studies reported its inhibitory effect against cancer-related targets including topoisomerase I and II (Topo I and II) [123] and human recombinant bone morphogenetic protein (BMP)-2, indicating that the cell growth inhibitory activity and the anticancer activity of dovitinib may result, in part, from its ability to target Topo I and II in addition to the ability to inhibit multiple kinases [124]. A study disclosed dovitinib inhibition of BMP-2 enhanced alkaline phosphatase (ALP) induction, which is a representative marker of osteoblast differentiation. Dovitinib also stimulated the translocation of phosphorylated Smad1/Smad5/Smad8 into the nucleus and phosphorylation of mitogen-activated protein kinases, including extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) and p38 Figure 5. An increase in the expression of mRNA of BMP-4, BMP-7, ALP, and osteocalcin (OCN) was noticed following treatment with (1). It was also noted that the potent stimulating
effect of (1) on BMP-2-induced osteoblast differentiation suggests a potential repositioning for the use of (1) treatment of bone-related disorders [124]. In a recent study, Ye Zhang et al. initially used the central scaffold 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one (12) to explore that potential diversification of functional groups decorating (12). The compounds synthesized were assessed against HepG2 (human liver cancer cells), SK-OV-3 (human ovarian cancer cells), NCI-H460 (human large cell lung cancer cells), BEL-7404 (human liver cancer cells), and HL-7702 (human liver normal cells) cell lines. Initial studies showed that halo-
genated derivative [3-(6-chloro-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one (15e) and 3-(6-bromo-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one (15f) (see Figure 4)] exhibited better activity than 5-FU and cisplatin when assessed against HepG2, SKOV-3, NCI-H460, and BEL-7404 but not HL-7702. The authors postulated that (15e) and (15f) inhibit HepG2 proliferation by blocking the cells in G2/M stage through activation of p53 protein.
2.2 Pyrazolobenzimidazoles as multikinase inhibitors

2.2.1 Discovery of AT9283a

In developing a selective potent aurora kinase inhibitor by employing fragment-based discovery method, the pyrazol-4-yl urea benzimidazole derivative (AT9283, 21) was identified as a multitargeting kinase inhibitor. The pyrazolebenzimidazole-based clinical candidate (21) was optimized by Steven Howard and his colleagues following efficient structure-guided fragment to hit IC_{50} as low as 3 nM activity as a dual potent inhibitor toward Aurora A/Aurora B [125]. AT9283 was identified starting from the pyrazole-benzimidazole fragment (16) that was previously identified during the endeavor of developing cyclin-dependent kinase (CDK) inhibitors. Subsequent structure-based approach using CDK2 crystallographic structure led to the identification of the benzamide analogue (18). Throughout the process of developing CDK2 inhibitors, pyrazole-benzimidazole derivative was identified to act with high potency toward Aurora A. Starting with fragment, (18) demonstrated superior ligand efficiency (LE = 0.59) for Aurora A compared to CDK1 and CDK2 and also sufficient potency to allow detection in a conventional enzyme bioassay [125].

Aiming at optimizing, the “hit” (18) on the way to end up with a lead SAR is performed on the benzamide analogues. The team was aided by polyploid phenotype in HCT116 cells, as a functional assay that differentiates for Aurora A and Aurora B inhibition, combined with potency when screening for further analogues. Guided by the hypothesis that introducing a basic motif into fragment (18) will improve the potency of the compound, modifications were introduced successfully to 5- or 6-position of the benzimidazole without causing any clashes with the protein. In a further step, the morpholinomethyl motif was functionalized at position 5. Details grasped from the X-ray crystal structure of (19) complexed with Aurora A revealed that the pyrazole-benzimidazole motif is positioned in an excellent complementarity with the narrow region of the ATP pocket. A result directed the steps to follow in the design of the optimized structure (Figure 6). While retaining the 5-morpholinomethyl on the pyrazole-benzimidazole motif, the benzamide portion was subjected to modifications. Keeping in mind the need to keep the molecular weight while introducing increased flexibility on the glycine region, the amide was converted to urea (20). This strategy was fruitful when comprehending that the urea analogue (20) exhibited reduced plasma protein binding while maintaining in vitro activity against Aurora kinases.

In the following step, the X-ray structure of (20) complexed with Aurora A was solved and iterated a similar binding mode to the hinge region. To resolve a twisted conformation of the phenyl plane in regard to pyrazole-benzimidazole portion of the molecule, a fully reduced cyclohexyl and difluorophenyl groups were also introduced (compound (20a) and (20b), respectively). Adsorption, disposition, metabolism, and excretion (ADME) considerations lead to proposing cyclopropyl derivative (21). As an alternative to introducing additional heterocyclic moiety, aiming at reducing the lipophilicity of (20a) for improving the ADME, the size of cyclohexyl ring was reduced to cyclopropyl analogue resulting in compound (21) that exhibits high enzyme and cellular potency still with reduced both the molecular weight (MW) and lipophilicity (log D7.4 = 2.1, MW = 381). Compound (21) demonstrated potent inhibition of HCT116 colony formation (IC_{50} = 12 nM), a clean CYP450 profile (IC_{50} > 10 μM for CYP3A4, 2D6, 1A2, 2C9, 2C19), acceptable mouse plasma protein binding (81.5%), and good thermodynamic solubility (2.0 mg/mL at pH = 7.0 and 13 mg/mL at pH = 5.5).

Later, AT9283 (21) was shown to bind and potently inhibit a number of kinases including the Aurora kinases A and B (serine–threonine kinases that are known to play essential roles in mitotic checkpoint control during mitosis at IC_{50} ~ 3 nM),
Janus kinase 2 (JAK2) and JAK3 (1.2 and 1.1 nM, respectively), breakpoint cluster region-Abelson (BCR-Abl) T315I (4 nM), and mitogen-activated protein kinase kinase kinase 2 (MEKK2) with IC\textsubscript{50} values of lower nanomolar (4.7–18 nM). This set of known kinases is known to play key roles in mitotic progress in cell cycle, induction of proliferation, evasion of apoptosis and tumor growth and thus considered vital targets to chemotherapeutic agents (see Table 1). Therefore, AT9283 is defined as multikinase (multitargeting) inhibitor [126].

AT-9283 inhibits effective proliferation of cancer cells both in vitro and in vivo with and its effect is enhanced by with other agents (see Table 2) [127]. Henceforth T9283 proceeded to clinical trials including in children with relapsed or refractory acute leukemia, imatinib-resistant BCR-Abl-positive leukemic cells, and patients with relapsed or refractory multiple myeloma. Accumulative results indicate a need for optimizing the pharmacological profile on the way to overcome faced challenges in clinical application of the compound [127, 128].

The activity in imatinib-resistant BCR-Abl chronic myelogeneous leukemia (CML) explained based on modeling which reiterated the assumption that AT-9283 is bound to the kinase domain in the “folded conformation” which allows the needed interactions with the hinge region without a clash between the cyclopropyl group and the isoleucine residue in the T315I mutant. The results obtained in
refractory CML suggest that AT-9283 can be efficient in Ph + acute lymphoblastic leukemia (Ph + ALL). It is the distinct binding mode that allows AT-9283 in similar manner to MK-0457 and PHA-739358 to exhibit potent activity against imatinib-resistant T315I mutant [127, 129].

2.2.2 Binding mode of AT-9283 (21) to kinases

Currently, there exist 11 X-ray resolved crystallographic structures of AT-9283 complexed with target proteins that are documented at the Protein Data Bank. They include aurora A, aurora B, mutant of aurora B, JAK2, and protein kinase A mutants as surrogate model for Aurora B. A closer look clarifies that in a similar manner to the binding of dovitinib, the benzene portion in benzimidazole fragment is pointing in an orientation toward the solvents’ exposed opening of the binding site. The pyrazole and urea fragments took part in multiple HBA and HBD interactions with the hinge region of the enzyme. The morpholine basic amine is oriented toward the solvent and enhanced significantly the solubility of the compound in physiological pH.

The crystal structure of compound (21) complexed with Aurora A is shown in Figure 7 [130]. The molecule is positioned at the ATP-binding site of the kinase. It is revealed the urea linker adopts a cis/trans configuration that results in the molecule having a “folded conformation.” This same conformation was also observed in the

| Enzyme          | IC₅₀ (nM)          |
|-----------------|--------------------|
| Aurora A       | 52% I at 3.0 nM    |
| Aurora B       | 58% I at 3.0 nM    |
| JAK3           | 1.1                |
| JAK2           | 1.2                |
| Abl (T315I)    | 4                  |
| GSK3-β, FGFR2, VEGFR3 (Flt4), Mer, Ret, Rsk2, Rsk3, Tyk2, Yes | 1–10 |
| Abl(Q252H), DRAK1, FGFR1, FGFR1(V561 M), FGFR2(NS49H), FGFR3, VEGFR1(Flt1), Flt-3, PDGFR-α(D842V), PDK1, PKC_μ, Rsk4, SRC(T341 M), VEGFR2 | 10–30 |

Table 1.
The inhibitory concentration 50% (IC₅₀ of the “lead” (21)) [126].

| Origin       | Cell line | IC₅₀ (nM) | p53 status |
|--------------|-----------|-----------|------------|
| Colon        | HCT116    | 13        | +          |
|              | HT-29     | 11        | —          |
|              | SW620     | 14        | —          |
| Ovarian      | A2780     | 77        | +          |
| Lung         | A549      | 12        | +          |
| Breast       | MCF7      | 20        | +          |
| Pancreatic   | MIA-Pa-Ca-2 | 7.8    | —          |

* + indicates expression of wild-type p53; − indicates no expression of p53 or that p53 is nonfunctional [126].

Table 2.
IC₅₀s are the mean of two or more independent determinations.
crystal structure of (21B) alone (Figure 8) and in DMSO. Such “folded conformation” was confirmed by NMR measurement. An NOE was observed between H3b/H3b’ of the cyclopropyl ring and the H4 and H7 protons of the benzimidazole ring. This “folded conformation” was explained by the occurrence of additional stabilization due to a hydrophobic interaction between these two groups.

The crystallographic structures of complexes both dovitinib-FGFR-1 and AT-9283 –Aurora A, revealed that there is a co-planarity between the benzimidazole and the quinolin-2-one of dovitinib, and pyrazole motif in AT-9283. A tautomeric rearrangement of the double bond induces a restriction on the rotation around the connection between the two fragments in each case (see Figure 8). This indicate the favorite binding to the less rotatable conformer (21B).

Recently AT-9283 was phase I/phase II trial of AT9283, a selective inhibitor of Aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia [131–137].

2.3 α-Haloacetamidobenzimidazole derivatives as multitargeting agents

Employing virtual screening methods of PubChem database as a first step, selected support vector machine (SVM) virtual hits were evaluated by Lipinski’s
The compounds which passed Lipinski’s rule of five were subject to further and more refined screening by using molecular docking. This sequential refinement led to the identification of 2-aryl benzimidazole group of derivatives as multitarget “EGFR, VEGFR-2, and PDGFR” inhibitors [138]. A mechanistic study reported by Jiang and colleagues displayed that (22) exhibited low to moderate micromolar IC\textsubscript{50} against nine established breast cancer cell lines that are known to have variable expressing EGFR and HER2 (MDA-MB-468, BT-549, MDA-MB-231, HCC1937, T-47D, BT-474, MDA-MB-453, ZR-75-1, MCF-7, and MCF-10 A). Using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, (24 and 25) exerts moderate inhibitory effect on growth of panel of breast cancer cell lines (IC\textsubscript{50} values of 2–9 μM) and was reported to be more potent than lapatinib against MDA-MB-468, BT-549, MDA-MB-231, ZR-75-1, and MCF-7. A correlation was observed between the level of HER2 and EGFR amplification and expression and the sensitivity toward (22). IC\textsubscript{50} = 3.58 μM against BT-474 (high expression of HER2), whereas against MDA-MB-453 (lower levels of HER2 expression) IC\textsubscript{50} = 4.91 μM. The activity against lower EGFR and HER2 expressing cell lines (ZR-75-1 and MCF-7), IC\textsubscript{50} = 1.81–2.99 μM was explained by the assumption that (22) is able to act via other targets of EGFR and HER2 [139].

Docking the compounds into kinase domains revealed that (22) occupies the ATP-binding site of EGFR (PDB: 2j6M). The compound was able to form a hydrogen bond with amino acid MET 793 (N–H⋯O:2.485 Å), claimed to be an important binding site of EGFR. The difference in the activity between the two compounds against VEGFR2 was explained by the difference in hydrogen bonding using docking into VEGFR-2 kinase. It was shown that (22) formed two hydrogen bonds with amino acids CYS917 (N–H⋯Cl:2.484 Å) and ASP1044 (N–H⋯O:2.429 Å), whereas compound (23) formed only one hydrogen bond with ASP1044 (N–H⋯O:2.419 Å) [140].

The authors concluded that electron-withdrawing substituent residing at 2-aryl ring together with shorter aliphatic chain contributed to the cytotoxic potency and to the induction of apoptosis by such group of compounds in HepG-2 cell lines. Though reported as multitargeting agent, the activity of 2-chloro-N-(2-\textit{p}-tolyl-\textit{1H}-benzo[d]imidazol-5-yl)acetamide (22) exhibiting most potency could not be explained explicitly by docking alone. (22) encompasses a reactive alphahaloacetamide (see Figure 9) that is vulnerable to nucleophilic substitution by biological
nucleophiles like thiols (-SH). Thus, a study to explore the formation of irreversible adducts with cellular proteins like kinases is recommended and hoped to uncover the principal mechanism of its wide action.

2.4 2-Anilino-4-(benzimidazol-2-yl)pyrimidines: a multikinase inhibitor scaffold

Anilinopyrimidines (Figure 10) displays a wide range of bioactivities. Asymmetric 2-anilinopyrimidines bearing 3-aminopropamides exhibit activity against epidermal growth factor receptor EGFR [141]. 2-anilinopyrimidine derivatives bearing 4-piperidino substituents exhibited improved and selective activity against triple-negative breast cancer cell line MDA-MB-468 believed to be due to EGFR inhibition. Decorating the pyrimidine nucleus with different substituents at position 4 endowed the final derivatives (4-substituted-2-anilinopyrimidine) with activity as well as selective toward corticotropin-releasing factor (CRF) antagonists [142]. Having the anilino fragment at 2- together with thiazolyl at 4- of the pyrimidine core was reported to exert antagonistic effect of cyclin-dependent kinase-2 (CKD2) [143], and improved inhibitory activity toward CDK9 and (CDK2) [143–145].

Bis-anilinopyrimidine was reported as potent and selective PAK1 inhibitor and as highly selective group I p21-activated kinase (PAK1) inhibitor [146]. Additionally, N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl] urea derivatives (see (27) at Figure 10) exhibit selective inhibition to class III receptor tyrosine kinase subfamily [147]. Other symmetric 4,6-dianilinopyrimidines induce selective EGFR inhibitions [148].

Notably, introducing the benzimidazolyl moiety at position 4 of the 2-anilinopyrimidine core to produce 2-anilino-4-(benzimidazol-2-yl)-pyrimidines renders such group of compounds’ activity against a wider range of kinases (see Figure 10).

Renate Determann et al. reported the synthesis and in vitro activity of a small library of compounds that are based on the 2-anilino-4-(benzimidazol-2-yl)-pyrimidine scaffold (Figure 10, (30)) [142]. The most potent derivative exhibited antiproliferative activity for several cancer cell lines of the NCI panel in submicromolar concentrations. SAR study was concluded in indicating a basic correlation with the anilinopyrimidine fragment and the substitution pattern at the aniline moiety. It is worth mentioning that 2-anilinopyrimidine fragment (Figure 10, (30)) is found in a range of kinase inhibitors.
Based on high-throughput screening method radiometric protein kinase assay (33PanQinase® Activity Assay) [149], 11 recombinant cancer-related protein kinases (AKT1, ARK5, Aurora B, AXL, FAK, IGF1-R, MET, PLK1, PRK1, SRC, VEGF-R2) were screened by a library of compounds. Interestingly, four kinases (Aurora B, FAK, PLK1, and VEGF-R2) proved to be of particular sensitivity to the tested compounds (Table 3). This group of four kinases is involved in oncogenesis and maintenance of vital processes of cancer. Thus it is believed that their concerted inhibition could be useful in the treatment of various malignancies. It is worth noting the infectivity of most of tested compounds, including the active ones against AKT1 (shown in Table 3).

2.4.1 2-Anilino-4-(benzimidazol-2-yl)pyrimidine-target interactions

Though the authors did not report a prudent SAR, however, docking compound (33) to ATP-binding pocket of PLK1 (PDB 2OWB) helped rationalize the initial observations [142]. One main reflection highlighted the positioning of the anilinopyrimidine fragment in the hinge region, forming a pair of hydrogen bonds to Cys133. Methoxy (CH$_3$O-) group at the position 2 of the aniline moiety forms a...
hydrogen bonding with the guanidine of Arg136 residing at the opening of the PLK1 ATP-binding pocket. The inactivity of derivatives with substituents bulkier than methoxy group (CH$_3$O-) was explained partially by the clash with Leu59 and Arg136 at the pocket entrance indicating limited tolerance to variation at this region.

2.5 Benzimidazolylamidines as multitargeting agents

Silvana Raić-Malić and colleagues reported the synthesis of a group of benzimidazole amidine derivatives [150]. Specifically, compound (Figure 11, (36)) abrogated the activity of several protein enzymes including tissue transglutaminase (TGM2) and kinases like CDK9, sphingosine kinase 1 (SK1), and p38 mitogen-activated protein kinase (p38 MAPK), whereas compound (37) did not have profound effect on CDK9 and TGM2 but showed moderate downregulation of SK1 and significant reduction in p38 MAPK.

A small library comprising 27 compounds was screened for the potency. Two of them, p-chlorophenyl-substituted 1,2,3-triazolyl derivatives of amidine N-isopropyl amidine (36) and imidazoline amidine (37), exhibited remarkable antiproliferative activities with IC$_{50}$ of 0.05 and 0.06 μM in non-small cell lung cancer cells A54 and was defined as multitarget inhibitors.

In their endeavor to look for potent inhibitors for treatment of non-small cell lung cancer, Silvana Raić-Malić and her team developed a group of benzimidazole amidine derivative that showed an inhibitory effect on several key players in cancer

|        | AKT1 ($>100$) | Aurora B ($7 \pm 2.3$) | FAK ($10.4 \pm 2.7$) | PLK1 ($6.0 \pm 0.1$) | VEGF-R2 ($75 \pm 2.0$) |
|--------|---------------|------------------------|----------------------|----------------------|------------------------|
| (32)   | $>100$        | $6.0 \pm 0.2$          | $3.4 \pm 0.8$        | $1.2 \pm 0.2$        | $7.2 \pm 0.3$          |
| (33)   | $>100$        | $>100$                 | $92$                 | $>100$               | $85$                   |

Compound (33) exhibited activities that range between IC$_{50}$ = 1.2 and 7.2 μM [142].

Table 3.
Protein kinase inhibition by (32 and 33) compared to pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (39) to standard multitargeting FDA-approved agents sorafenib and sunitinib.
proliferation [150]. A recent study reported that synthesis of amidino 2-substituted benzimidazoles linked to 1,4-disubstituted 1,2,3-triazoles by applying microwave and ultrasound irradiation in click reaction and subsequent condensation of thus obtained 4-(1,2,3-triazol-1-yl)benzaldehyde with o-phenylenediamines. The study concluded the improved cytotoxic effect (within the nanomolar range; IC\textsubscript{50} of 50 and 60 nM) against hepatocellular carcinoma cells. A follow-up study affirms the conclusion that when benzimidazole is conjugated to 1,2,3-triazole moiety, the hybrid exerts potent and selective antiproliferative effect against a panel of cell lines [non-small cell lung cancer (A549), ductal pancreatic adenocarcinoma (CFPAC-1), cervical carcinoma (HeLa), and metastatic colorectal adenocarcinoma (SW620) as well as on normal human lung fibroblasts (WI38)] with 5-fluorouracil (5FU) as a positive control. Two hits (36) and (37) (Figure 11a) demonstrated a potent activity at nM range (IC\textsubscript{50} of 50 and 60 nM) against non-small cell lung cancer (A549). Interestingly, benzyl-substituted 1,2,3-triazolyl analogue of imidazoline (36) exhibited a remarkable and selective activity (IC\textsubscript{50} = 0.07 μM) on A549 cell line. A mechanistic study performed on A549 cell line using Western blotting reinforced the belief that nature of aromatic substituent of 1-(1,2,3-triazolyl) and amidino moiety at C-5 position of benzimidazole ring is critical to the cytostatic activity of this group of compounds. In silico analysis supported the conception that (36) is bound slightly better than (37) to ATP-binding site of p38 MAPK, which correlates with observed decrement in the expression level of phospho-p38 MAPK displayed by (36). The importance of triazole was referred to its ability to form one H-bond with Met109 in the hinge region. Aminobenzimidazole group forms a number of HB with polar amino acids Glu71, His148, and Asp168 in the linker region. Phenyl moieties found on the hybrid both are placed in the hydrophobic environment. The phenyl connected to the triazole is assumed to participate in a π-π stacking with Phe169 (see Figure 11). The study reported (36) as a multitarget inhibitor since it abrogated the activity of several protein kinases including TGM2, CDK9, SK1, and p38 MAPK.

Figure 11. (a) Hit compounds prepared and screened for multitarget action 2-(4-((1-Benzyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-5-(4,5-dihydro-1H-imidazol-2-yl)-1H-benzo[d]imidazole hydrochloride (36), 2-(4-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-N-isopropyl-1H-benzo[d]imidazole-6-carboximidamide (37); (b) summary of structure–activity relationship of benzimidazolylamidines [150].
3. Conclusion

3.1 Multitargeting and polypharmacology

According to the definition of Richard Morphy, the multitarget drugs are defined as “compounds that are designed to modulate multiple targets of relevance to a disease, with the overall goal of enhancing efficacy and/or improving safety” (Morphy, Rankovic, 2005) [151].

Modulating the function of numerous biological molecules is a well-established pharmacological approach in medicine practice. Paracetamol, a traditional therapeutic used worldwide, is believed to induce its effects via action on multiple targets. Several psychoactive, serotonergic, cholinergic, and adrenergic agonists or antagonists exercise their actions on a wider range of singular biomolecular target.

Apart from the alphachloroacetamidobenimidzoles (22), the groups of compounds reported so far in the literature as multitarget agents act in most cases on receptor tyrosine kinases (RTKs) as competitive ATP inhibitors. Those by virtue occupy the vicinity of ATP with the heteroaromatic system interactively buried in the purine portion pocket and interact with the hinge region of the kinase domain. The thiol (-SH)-π and the stacking π-π together with the hydrophobic interaction with the floor and the ceiling of the purine-binding regions are believed to do the required binding adjustment as kinase inhibitors. Crystallographic structure of dovitinib human FGFR1 revealed the occupancy of the purine-binding regions (part of the ATP-binding site) with the quinolinone-benzimidazole fragment, while the N-methylpiperazine attached to C5’ at the phenyl part of the benzimidazole is pointing toward the opening and is exposed to the solution. Thus, it seems that benzimidazole portion is not interacting directly with the hinge region of the enzyme. Similar binding is noticed with AT9382. The pyrazolylbenzimidazole and the benzamide motif take part in HBD-HBA bridging with the hinge of the kinase domain.

In the case of 2-anilino-4-(benzimidazole-2-yl)pyrimidine, the benzimidazole portion looks immersed deep in the purine-binding regions of the ATP-binding site participating in direct interactions via hydrogen bonding and hydrophobic interactions, while the hydroxymethoxyaniline portion points towards the solvent exposed area.

3.2 Lessons learnt

3.2.1 Discovery methods

Despite the imbedded potential, the multitarget activity of the reported benzimidazole-based scaffolds was identified serendipitously. In other words, none of the benzimidazole anticancer multitargeting agents seem to be identified in unforeseen manner, and in many ways they emerge with no intention to be designed initially. While adhering to the development of selective and specific agents, results accumulated afterward revealed multitarget action. For example, 3-benzimidazol-2-ylhydroquinolin-2-one scaffold [benzimidazolylquinolinone (Figure 4, (12))] was identified using high-throughput screening (HTS). AT9283 (Figure 6, (21)) was identified following fragment-based structural approach with the initial aim to develop an Aurora selective inhibitor, and later it was reported to act as multitargeting agent.

It is hoped that the identification, discovery, and optimization of benzimidazole-based multitargeting anticancer agent will benefit from the “big data era” fueled by data available from public repositories.
3.2.2 Shift in the paradigm

Multitargeting can occur via three possible ways: acting on the same target, on different targets of the same pathway, or on different targets of different pathways. So far the benzimidazole derivatives that have been explored are reported to act as the third category “acting on different targets of different pathways.” The focus has been so far on the kinome-relevant signaling key player with dovitinib widening the landscape to non-kinase targets. Broadening “multitargeting” concept to identify novel inhibitors with potency against key targets outside the human kinome necessitates treating complex diseases using “polypharmacology” gains special interest in resistant mutated spreadable cancers [151].

Despite the initial enthusiasm for the efficacy of molecular targeted therapeutics following the approval of imatinib, a small tyrosine kinase inhibitor targeting BCR-Abl, in chronic myeloid leukemia (CML) and trastuzumab, a monoclonal antibody against HER2, for treatment of metastatic breast cancer, scientists and clinicians were challenged by recurrent relapse due to cancer patients who developed drug resistance. In the case of RTKIs, resistance can emerge as a result of selection for mutant sin in the target that renders the binding site inaccessible, reduced influx accompanied by enhance efflux, shift in metabolism and excretion of the drug, and the activation of alternative signaling pathways. Thus, the rationale for targeting drugs is shifting. In the last two decades, the main effort was aimed at developing highly specific inhibitors acting on single target. Now, there is a general agreement that molecules interfering simultaneously with multiple RTKs might be more effective than single-target agents. With the recent approval by the FDA of sorafenib, regorafenib, sunitinib, lenvatinib, and axitinib-targeting VEGFR, PDGFR, FLT-3, and c-KIT—more attention is drawn to broad-spectrum anticancer properties multikinase targeting drugs. Thus it is anticipated that more multitargeting agents will be getting into clinical trials and making their way to clinical application. It is hoped that identification, discovery, and optimization of benzimidazole-based multitargeting agents will benefit from the “big data era” fueled by the availability of big data, advances in technology, and artificial intelligence.

Acknowledgements

The author would like to acknowledge “Zamala” Program: University Fellowship Program in Palestinian Universities (http://www.taawon.org/ar/zamala) for the fund granted to make this research stay at London Regional Cancer Center, Western University Ontario, Canada, possible. Also, I would like to acknowledge my home institution Al-Quds University, Jerusalem-Palestine, for the support and encouragement. In addition, I wish to thank the editor and high value the editor’s work, reading, and comments. The accomplishment of this chapter was made possible thanks to such support and help.

Conflict of interest

No conflict of interest exists.

Notes/thanks/other declarations

I would like to express my special thanks, gratitude and truthful appreciation to my dearest family: my wife Muna, my daughters Aseel and Layan and my sons
Mulham and Majd for all the love, compassion, and support I received from them all along.

This chapter is dedicated to the respectable memories of my mother Jaleelah and father Salem who died of old age and to the reminiscence of my dearest brother Mohammed who left this world due to leukemia. Peace Be Upon Them All.

### Acronyms and abbreviations

| Acronym | Definition |
|---------|------------|
| MTT     | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide |
| PRK1    | actin-regulating kinase |
| MEK1    | activated protein kinase |
| AML     | acute myeloid leukemia |
| ADME    | adsorption, disposition, metabolism, excretion |
| ARK5    | AMPK-related kinase 5 |
| ALK     | anaplastic lymphoma kinase |
| ALP     | alkaline phosphatase |
| AXL     | “anexelektro” receptor tyrosine kinase |
| BCR-Abl | breakpoint cluster region-Abelson kinase |
| CK2     | casein kinase 2 |
| CXCR3   | chemokine receptor |
| CML     | chronic myelogenic leukemia |
| DHODH   | dihydroorotate dehydrogenase |
| D2R     | dopamine receptor 2 |
| FGFR-1/FGFR-2/FGFR-3 | fibroblast growth factor receptors 1, 2, 3 |
| FAK     | focal adhesion kinase |
| IC₅₀    | half maximal inhibitory concentration |
| HGF or MET | hepatocyte growth factor |
| H4H     | histamine receptors 4 |
| HDAC2   | histone deacetylase 2 |
| MDA-MB-468 | human breast carcinoma cell lines |
| HER2    | human epidermal growth factor receptor 2 |
| HB      | hydrogen bind |
| HBD     | hydrogen bond donor |
| HBA     | hydrogen bond acceptor |
| 5-HTR   | hydroxytryptamine receptors |
| CDK     | inhibition of cyclin-dependent kinases |
| IGF-1R  | insulin-like growth factor 1 receptor |
| ITK     | interleukin 2-inducible T-cell kinase |
| JAK-1/JAK-2/JAK-3 | Janus kinase-1/2/3 |
| LE      | ligand efficiency |
| Lck     | lymphocyte tyrosine kinase |
| MEKK2   | mitogen-activated protein kinase kinase kinase 2 |
| nM      | nanomolar |
| μM      | micromolar |
| PAK1    | p21-activated kinase |
| p38 MAPK | p38 mitogen-activated protein kinase |
| Ph + ALL | Ph + acute lymphoblastic leukemia |
| PI3K    | phosphatidylinositol 3-kinase |
| PDGFR-α/β | platelet-derived growth factor receptor-α/β |
| PLK-1   | polo-like kinase 1 |
| PARP-1  | poly(ADP-ribose)polymerase-1 |
| Abbreviation | Full Form |
|--------------|-----------|
| ATP          | adenosine triphosphate |
| PDB          | Protein Data Bank |
| AKT1         | RAC-alpha serine/threonine-protein kinase |
| PTKs         | protein tyrosine kinase |
| PTP          | protein tyrosine phosphatases |
| c-KIT        | stem cell factor receptor |
| FLT3         | FMS-like tyrosine kinase 3 |
| FLT3-ITD     | FMS-like tyrosine kinase 3 internal tandem duplication |
| SAR          | structure–activity relationship |
| SVM          | support vector machines |
| ATR          | telangiectasia and Rad3-related protein kinase |
| TOPO1/TOPO2  | topoisomerase 1/2 |
| TKRs         | tyrosine kinase receptors |
| VEGFR-1/VEGFR-2/VEGFR-3 | vascular endothelial growth factor receptor-1, 2, 3 |
| SRC          | v-src sarcoma (Schmidt-Ruppin A-2) viral onco gene homolog (avian) |

**Author details**

Yousef Najajreh  
Anticancer Drugs Research Lab, Faculty of Pharmacy, Al-Quds University, Jerusalem, Palestine

*Address all correspondence to: y.s.najajreh@gmail.com*

---

**IntechOpen**  
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References

[1] Salahuddin, Shaharyar M, Mazumder A. Benzimidazoles: A biologically active compounds. Arabian Journal of Chemistry. 2017

[2] Bansal Y, Silakari O. The therapeutic journey of benzimidazoles: A review. Bioorganic & Medicinal Chemistry. 2012

[3] Yadav G, Ganguly S. Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: A mini-review. European Journal of Medicinal Chemistry. 2015

[4] Walia R, Naaz SF, Iqbal K, Lamba HS. Benzimidazole derivatives—An overview. International Journal of Research in Pharmaceutical Chemistry. 2011

[5] Ahamad A, Pandurangan A, Rana K, Tiwari AK, Singh N, Anand P. Benzimidazole: A short review of their antimicrobial activities. International Current Pharmaceutical Journal. 2012

[6] Kathiravan MK, Salake AB, Chothe AS, Dudhe PB, Watode RP, Mukta MS, et al. The biology and chemistry of antifungal agents: A review. Bioorganic & Medicinal Chemistry. 2012

[7] Shah K, Chhabra S, Shrivastava SK, Mishra P. Benzimidazole: A promising pharmacophore. Medicinal Chemistry Research. 2013

[8] Sachs G, Shin JM, Howden CW. Review article: The clinical pharmacology of proton pump inhibitors. Alimentary Pharmacology and Therapeutics. 2006

[9] Sharma MC, Kohli DV, Sharmab S, Sharma AD. Synthesis and antihypertensive activity of some new benzimidazole derivatives of 4′-(6-methoxy-2-substituted-benzimidazole-1-ylmethyl)-biphenyl-2-carboxylic acid in the presences of BF3·OEt2. Der Pharmacia Sinica. 2010

[10] Shah DI, Sharma M, Bansal Y, Bansal G, Singh M. Angiotensin II-AT1 receptor antagonists: Design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives. European Journal of Medicinal Chemistry. 2008

[11] Sakamoto H, Ojima M, Kubo K, Fuse H, Tanaka M, Kohara Y, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, Azilsartan, in receptor binding and function studies. Journal of Pharmacology and Experimental Therapeutics. 2010

[12] Zhang J, Liu X, Wang SQ, Liu KY, Xu WR, Cheng XC, et al. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan. Journal of Biomolecular Structure and Dynamics. 2017

[13] Achar KCS, Hosamani KM, Seetharamareddy HR. In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives. European Journal of Medicinal Chemistry. 2010

[14] Rathore A, Sudhakar R, Ahsan MJ, Ali A, Subbarao N, Jadav SS, et al. In vivo anti-inflammatory activity and docking study of newly synthesized benzimidazole derivatives bearing oxadiazole and morpholine rings. Bioorganic Chemistry. 2017

[15] Bukhari SNA, Lauro G, Jantan I, Chee CF, Amjad MW, Bifulco G, et al. Anti-inflammatory trends of new benzimidazole derivatives. Future Medicinal Chemistry. 2016

[16] Padalkar VS, Borse BN, Gupta VD, Phatangare KR, Patil VS, Umape PG, et al. Synthesis and antimicrobial activity of novel 2-substituted benzimidazole, benzoxazole and
benzothiazole derivatives. Arabian Journal of Chemistry. 2016

[17] Zhang HZ, Damu GLV, Cai GX, Zhou CH. Design, synthesis and antimicrobial evaluation of novel benzimidazole type of fluconazole analogues and their synergistic effects with chloromycin, norfloxacin and fluconazole. European Journal of Medicinal Chemistry. 2013

[18] Özkay Y, Tunali Y, Karaca H, Işıkdağ I. Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazone moiety. European Journal of Medicinal Chemistry. 2010

[19] Tonelli M, Simone M, Tasso B, Novelli F, Boido V, Sparatore F, et al. Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. Bioorganic & Medicinal Chemistry. 2010

[20] Budow S, Kozłowska M, Gorska A, Kazimierczuk Z, Eickmeier H, La Colla P, et al. Substituted benzimidazoles: Antiviral activity and synthesis of nucleosides. ARKIVOC. 2009

[21] Li YF, Wang GF, He PL, Huang WG, Zhu FH, Gao HY, et al. Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. Journal of Medicinal Chemistry. 2006

[22] Elnima EI, Zubair MU, Al-Badr AA. Antibacterial and antifungal activities of benzimidazole and benzoxazole derivatives. Antimicrobial Agents and Chemotherapy. 1981

[23] Bai YB, Zhang AL, Tang JJ, Gao JM. Synthesis and antifungal activity of 2-chloromethyl-1H-benzimidazole derivatives against phytopathogenic fungi in vitro. Journal of Agricultural and Food Chemistry. 2013

[24] Singla P, Luxami V, Paul K. Benzimidazole-biologically attractive scaffold for protein kinase inhibitors. RSC Advances. 2014

[25] Prichard R. Anthelmintic resistance. Veterinary Parasitology. 1994

[26] Martin RJ. Modes of action of anthelmintic drugs. Veterinary Journal. 1997

[27] Gurvinder S, Maninderjit K, Mohan C. Benzimidazole: The latest information of biological activities. International Research Journal of Pharmacy. 2013

[28] Brown HD, Matzuk AR, Ilves IR, Peterson LH, Harris SA, Sarett LH, et al. Antiparasitic drugs. IV. 2-(4′-thiazolyl)benzimidazole, a new anthelmintic. Journal of the American Chemical Society. 1961

[29] Nofal ZM, Soliman EA, Abd El-Karim SS, El-Zahar MI, Srour AM, Sethumadhavan S, et al. Novel benzimidazole derivatives as expected anticancer agents. Acta Poloniae Pharmaceutica. Drug Research. 2011

[30] Shaharyar M, Abdullah MM, Bakht MA, Majeed J. Pyrazoline bearing benzimidazoles: Search for anticancer agent. European Journal of Medicinal Chemistry. 2010

[31] Refaat HM. Synthesis and anticancer activity of some novel 2-substituted benzimidazole derivatives. European Journal of Medicinal Chemistry. 2010

[32] Paul K, Sharma A, Luxami V. Synthesis and in vitro antitumor evaluation of primary amine substituted quinazoline linked benzimidazole. Bioorganic & Medicinal Chemistry Letters. 2014

[33] Patil A, Ganguly S, Surana S. A systematic review of benzimidazole derivatives as an antiulcer agent. Rasayan Journal of Chemistry. 2008
[34] Sivakumar R, Pradeepchandran R, Jayaveera KN, Kumarnallasivan P, Vijaianand PR, Venkatnarayanan R. Benzimidazole: An attractive pharmacophore in medicinal chemistry. International Journal of Pharmaceutical Research. 2011

[35] Ganie AM, Dar AM, Khan FA, Dar BA. Benzimidazole derivatives as potential antimicrobial and antiulcer agents: A mini review. Mini Reviews in Medicinal Chemistry. 2018

[36] Gurer-Orhan H, Orhan H, Suzen S, Püsküllü MO, Buyukbingol E. Synthesis and evaluation of in vitro antioxidant capacities of some benzimidazole derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry. 2006

[37] Mavrova AT, Yancheva D, Anastassova N, Anichina K, Zvezdanovic J, Djordjevic A, et al. Synthesis, electronic properties, antioxidant and antibacterial activity of some new benzimidazoles. Bioorganic & Medicinal Chemistry. 2015

[38] Rajasekaran S, Rao G, Chatterjee A. Synthesis, anti-inflammatory and anti-oxidant activity of some substituted benzimidazole derivatives. International Journal of Drug Development and Research. 2012

[39] Ueno H, Katoh S, Yokota K, Hoshi JI, Hayashi M, Uchida I, et al. Structure-activity relationships of potent and selective factor Xa inhibitors: Benzimidazole derivatives with the side chain oriented to the prime site of factor Xa. Bioorganic & Medicinal Chemistry Letters. 2004

Biotransformation of the immunomodulator, 3-(p-chlorophenyl)-2,3-dihydro-3-hydroxythiazolo[3,2a]benzimidazole-2-acetic acid, and its relationship to thyroid toxicity. Toxicology and Applied Pharmacology. 1981

[42] Oe T, Aramori I, Hosogai N, Mutoh S, Konishi S, Fujimura T, et al. FK614, a novel peroxisome proliferator-activated receptor γ modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. Journal of Pharmacological Sciences. 2005

[43] Fujimura T, Sakuma H, Konishi S, Oe T, Hosogai N, Kimura C, et al. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. Journal of Pharmacological Sciences. 2005

[44] Oh S, Ha H-J, Chi D, Lee H. Serotonin Receptor and Transporter Ligands - Current Status. Curr Med Chem. 2012

[45] Ramot Y, Mastrofrancesco A, Camera E, Desreumaux P, Paus R, Picardo M. The role of PPARγ-mediated signalling in skin biology and pathology: New targets and opportunities for clinical dermatology. Experimental Dermatology. 2015

[46] Huang THW, Teoh AW, Lin BL, DSH L, Roufogalis B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacological Research. 2009

[47] Trémollières F, Lopes P. Specific estrogen receptor modulators (SERMS). Les Modul spécifiques des récepteurs œstrogéniques. 2002

[48] Gür ZT, Çalışkan B, Banoglu E. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular
leukotriene biosynthesis. European Journal of Medicinal Chemistry. 2018

[49] Aboul-Enein HY. Benzimidazole derivatives as antidiabetic agents. Med Chem (Los Angeles). 2015

[50] Bathini P, Kameshwari L, Vijaya N. Antidiabetic effect of 2 nitro benzimidazole in alloxan induced diabetic rats. International Journal of Basic & Clinical Pharmacology. 2013

[51] Spasov AA, Vassiliev PM, Lenskaya KV, Anisimova VA, Kuzmenko TA, Morkovnik AS, et al. Hypoglycemic potential of cyclic guanidine derivatives. Directed search, pharmacology, clinics. Pure and Applied Chemistry. 2017

[52] Robinson MW, McFerran N, Trudgett A, Hoey L, Fairweather I. A possible model of benzimidazole binding to β-tubulin disclosed by invoking an inter-domain movement. Journal of Molecular Graphics & Modelling. 2004

[53] Aguayo-Ortiz R, Méndez-Lucio O, Romo-Mancillas A, Castillo R, Yépez-Mulia L, Medina-Franco JL, et al. Molecular basis for benzimidazole resistance from a novel β-tubulin binding site model. Journal of Molecular Graphics & Modelling. 2013

[54] Silvestre A, Humbert JF. Diversity of benzimidazole-resistance alleles in populations of small ruminant parasites. International Journal for Parasitology. 2002

[55] Kwa MSG, Veenstra JG, Roos MH. Molecular characterisation of β-tubulin genes present in benzimidazole-resistant populations of Haemonchus contortus. Molecular and Biochemical Parasitology. 1993

[56] Pjura PE, Grzeskowiak K, Dickerson RE. Binding of Hoechst 33258 to the minor groove of B-DNA. Journal of Molecular Biology. 1987

[57] Stella S, Cascio D, Johnson RC. The shape of the DNA minor groove directs binding by the DNA-bending protein Fis. Genes & Development. 2010

[58] Nelson SM, Ferguson LR, Denny WA. Non-covalent ligand/DNA interactions: Minor groove binding agents. Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis. 2007

[59] Andrić D, Roglić G, Šukalović V, Šoškić V, Kostić-Rajačić S. Synthesis, binding properties and receptor docking of 4-halo-6-[2-(4-arylpiperazin-1-yl)ethyl]-1H-benzimidazoles, mixed ligands of D2 and 5-HT1A receptors. European Journal of Medicinal Chemistry. 2008

[60] Siracusa MA, Salerno L, Modica MN, Pittalà V, Romeo G, Amato ME, et al. Synthesis of new arylpiperazinylalkylthiobenzimidazole, benzothiazole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands. Journal of Medicinal Chemistry. 2008

[61] Avila D, Frechilla D, Río JD, López-Rodríguez ML, Morcillo MJ, Schiapparelli L, et al. Design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands. Bioorganic & Medicinal Chemistry Letters. 2003

[62] Andrić D, Tovilović G, Roglić G, Šoškić V, Tomić M, Kostić-Rajačić S. 6-[2-(4-Arylpiperazin-1-yl)ethyl]-4-halo-1,3-dihydro-2H-benzimidazole-2-thiones: Synthesis and pharmacological evaluation. Journal of the Serbian Chemical Society. 2007

[63] Fernandes JPS, Pasqualoto KFM, Ferreira EI, Brandt CA. Molecular modeling and QSAR studies of a set of indole and benzimidazole derivatives as H4 receptor antagonists. Journal of Molecular Modeling. 2011
[64] Šukalović V, Andrić D, Roglić G, Kostić-Rajačić S, Schrattenholz A, Šoškić V. Synthesis, dopamine D2 receptor binding studies and docking analysis of 5-[(4-arylpiperazin-1-yl)propyl]-1H-benzimidazole, 5-[(4-arylpiperazin-1-yl)ethoxy]-1H-benzimidazole and their analogs. European Journal of Medicinal Chemistry. 2005

[65] Hayes ME, Wallace GA, Grongsaard P, Bischoff A, George DM, Miao W, et al. Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3. Bioorganic & Medicinal Chemistry Letters. 2008

[66] Moriarty KJ, Takahashi H, Pullen SS, Khine HH, Sallati RH, Raymond EL, et al. Discovery, SAR and X-ray structure of 1H-benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk). Bioorganic & Medicinal Chemistry Letters. 2008

[67] Zhang G, Ren P, Gray NS, Sim T, Liu Y, Wang X, et al. Discovery of pyrimidine benzimidazoles as Lck inhibitors: Part I. Bioorganic & Medicinal Chemistry Letters. 2008

[68] Yaguchi SI, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. Journal of the National Cancer Institute. 2006

[69] Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, et al. Biological characterization of ATRR-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clinical Cancer Research. 2007

[70] Bueno OF. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. The EMBO Journal. 2002

[71] Antony SA, Sam Daniel Prabu D, Ramalakshmi N, Lakshmanan S, Thirumurugan K, Govindaraj D. Synthesis, characterization of benzimidazole carboxamide derivatives as potent anaplastic lymphoma kinase inhibitor and antioxidant activity. Synthetic Communications. 2019

[72] Long T, Neitz RJ, Beasley R, Kalyanaraman C, Suzuki BM, Jacobson MP, et al. Structure-bioactivity relationship for benzimidazole thiophene inhibitors of polo-like kinase 1 (PLK1), a potential drug target in Schistosoma mansoni. PLoS Neglected Tropical Diseases. 2016

[73] Blake DG, Green SR, Flynn CJ, Glover DM, Rogers NL, Emery A, et al. Abstract 4435: Discovery, biological characterization and oral antitumor activity of polo-like kinase 1 (PLK1) selective small molecule inhibitors. Cancer Research. 2011

[74] Hong S, Kim J, Yun SM, Lee H, Park Y, Hong SS, et al. Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-abelson kinase including the T315i mutant. Journal of Medicinal Chemistry. 2013

[75] Sarino S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A, et al. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (‘casein kinase-2’). FEBS Letters. 2001

[76] Charrier JD, Durrant SJ, Golec JMC, Kay DP, Knechtel RMA, MacCormick S, et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. Journal of Medicinal Chemistry. 2011

[77] Mathias TJ, Natarajan K, Shukla S, Doshi KA, Singh ZN, Ambudkar SV, et al. The FLT3 and PDGFR
inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Investigational New Drugs. 2015

[78] Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. Journal of Medicinal Chemistry. 2009

[79] Abdullah I, Chee CF, Lee YK, Thunuguntla SSR, Satish Reddy K, Nellore K, et al. Benzimidazole derivatives as potential dual inhibitors for PARP-1 and DHODH. Bioorganic & Medicinal Chemistry. 2015

[80] Penning TD, Zhu GD, Gandhi VB, Gong J, Thomas S, Lubisch W, et al. Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. Bioorganic & Medicinal Chemistry. 2008

[81] Zhou D, Chu W, Xu J, Jones LA, Peng X, Li S, et al. Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorganic & Medicinal Chemistry. 2014

[82] Canan S, Webber SE, Newell DR, Thomas HD, Skalitzky D, Batey MA, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular Cancer Therapeutics. 2007

[83] Singh A, Maqbool M, Mobashir M, Hoda N. Dihydroorotate dehydrogenase: A drug target for the development of antimalarials. European Journal of Medicinal Chemistry. 2017

[84] Bansal S, Sur S, Tandon V. Benzimidazoles: Selective inhibitors of topoisomerase I with differential modes of action. Biochemistry. 2019

[85] Ishida T, Suzuki T, Hirashima S, Mizutani K, Yoshida A, Ando I, et al. Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: Identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole. Bioorganic & Medicinal Chemistry Letters. 2006

[86] Ryu K, Kim ND, Choi SI, Han CK, Yoon JH, No KT, et al. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorganic & Medicinal Chemistry. 2009

[87] Adegboye AA, Khan KM, Salar U, Aboaba SA, Kanwal, Chigurupati S, et al. 2-Aryl benzimidazoles: Synthesis, α-amylase inhibitory activity, and molecular docking study. European Journal of Medicinal Chemistry. 2018

[88] Patil VM, R GK, Chudayeu M, Prakash Gupta S, Samanta S, Masand N, et al. Synthesis, in vitro and in silico NS5B polymerase inhibitory activity of benzimidazole derivatives. Medicinal Chemistry (Los Angeles). 2012

[89] Romero-Castro A, León-Rivera I, Ávila-Rojas LC, Navarrete-Vázquez G, Nieto-Rodríguez A. Synthesis and preliminary evaluation of selected 2-aryl-5(6)-nitro-1H-benzimidazole derivatives as potential anticancer agents. Archives of Pharmacal Research. 2011

[90] Yoon YK, Choon TS. Structural modifications of benzimidazoles via multi-step synthesis and their impact on sirtuin-inhibitory activity. Archiv der Pharmazie (Weinheim). 2016

[91] Tamura Y, Hayashi K, Omori N, Nishiura Y, Watanabe K, Tanaka N, et al.
Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile. Bioorganic & Medicinal Chemistry Letters. 2013

[92] Song WJ, Lin QY, Jiang WJ, Du FY, Qi QY, Wei Q. Synthesis, interaction with DNA and antiproliferative activities of two novel Cu(II) complexes with norcantharidin and benzimidazole derivatives. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2015

[93] Schäer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Almaladas N, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Reports. 2018

[94] Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, et al. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 2016

[95] Lim JSJ, Turner NC, Yap TA. CDK4/6 inhibitors: Promising opportunities beyond breast cancer. Cancer Discovery. 2016

[96] Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology & Oncology. 2017

[97] Deng Z, Yu L, Cao W, Zheng W, Chen T. Rational design of ruthenium complexes containing 2,6-bis(benzimidazolyl)pyridine derivatives with radiosensitization activity by enhancing p53 activation. ChemMedChem. 2015

[98] Melisi D, Piro G, Tamburrino A, Carbone C, Tortora G. Rationale and clinical use of multitargeting anticancer agents. Current Opinion in Pharmacology. 2013

[99] Li YH, Wang PP, Li XX, Yu CY, Yang H, Zhou J, et al. The human kinome targeted by FDA approved multi-target drugs and combination products: A comparative study from the drug-target interaction network perspective. PLoS One. 2016

[100] Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. The New England Journal of Medicine. 2005

[101] Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemotherapy Research and Practice. 2014

[102] Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, et al. Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: Clinical activity and biological correlations. Annals of Oncology. 2008

[103] Proschak E, Stark H, Merk D. Polypharmacology by design: A medicinal chemist's perspective on multitargeting compounds. Journal of Medicinal Chemistry. 2019

[104] Narayanan D, Gani OABSM, Gruber FXE, Engh RA. Data driven polypharmacological drug design for lung cancer: Analyses for targeting ALK, MET, and EGFR. Journal of Cheminformatics. 2017

[105] Hong WK, Kim ES, Lee JJ, Wistuba I, Lippman S. The landscape of cancer prevention: Personalized approach in lung cancer. Cancer Research. 2011

[106] Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, et al. Design, structure-activity relationships and in vivo characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones:
Novel class of receptor tyrosine kinase inhibitors. Journal of Medicinal Chemistry. 2009

[107] Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005

[108] Pyo K-H, Cho BC, Kim H, Moon YW, Jang KW, Kang HN, et al. Antitumor activity and acquired resistance mechanism of dovitinib (TKI258) in RET-rearranged lung adenocarcinoma. Molecular Cancer Therapeutics. 2015

[109] Lopes De Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, et al. CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clinical Cancer Research. 2005

[110] Lee CK, Lee ME, Lee WS, Kim JM, Park KH, Kim TS, et al. Dovitinib (TKI258), a multi-targeted angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. American Journal of Cancer Research. 2015

[111] Valverde A, Gomez-Espana A, Hernandez V, Jimenez J, Lopez-Sanchez LM, Cano MT, et al. The multi-targeted kinase inhibitor aee788 exerts anti-proliferative effects in braf mutated colorectal cancer cells. Annals of Oncology. 2010

[112] André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, et al. Targeting FGFR with dovitinib (TKI258): Preclinical and clinical data in breast cancer. Clinical Cancer Research. 2013

[113] Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clinical Cancer Research. 2013

[114] Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, et al. A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier Cancer Research Network trial HCRN 12-157. Clinical Cancer Research. 2017

[115] Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Research. 2017

[116] Schäfer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, et al. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. Journal of Cancer Research and Clinical Oncology. 2016

[117] Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, Gupta A, et al. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. Lung Cancer. 2017

[118] Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, et al. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: A non-randomised, open-label, two-group, two-stage, phase 2 study. The Lancet Oncology. 2015

[119] Bunney TD, Wan S, Thiagarajan N, Sutto L, Williams SV, Ashford P, et al. The effect of mutations on drug sensitivity and kinase activity of fibroblast growth factor receptors: A combined experimental and theoretical study. eBioMedicine. 2015
[120] Klein T, Vajpai N, Phillips JJ, Davies G, Holdgate GA, Phillips C, et al. Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase. Nature Communications. 2015

[121] Tucker JA, Klein T, Breed J, Breeze AL, Overman R, Phillips C, et al. Structural insights into FGFR kinase isoform selectivity: Diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. Structure. 2014

[122] Lesca E, Lammens A, Huber R, Augustin M. Structural analysis of the human fibroblast growth factor receptor 4 kinase. Journal of Molecular Biology. 2014

[123] Hasinoff BB, Wu X, Nitiss J, Kanagasabai R, Yalowich JC. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochemical Pharmacology. 2012

[124] A receptor tyrosine kinase inhibitor, dovitinib (TKI-258), enhances BMP-2-induced osteoblast differentiation in vitro. Molecules and Cells. 2016

[125] Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. Journal of Medicinal Chemistry. 2009

[126] Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, et al. Aurora B kinase inhibition in mitosis: Strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle. 2009

[127] Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood. 2010

[128] Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clinical Cancer Research. 2011

[129] Smyth T, Reule M, Yokota A, Ottmann OG, Nagao R, Tanaka R, et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood. 2010

[130] Puleo DE, Kucera K, Hammaren HM, Ungureanu D, Newton AS, Silvennoinen O, et al. Identification and characterization of JAK2 pseudokinase domain small molecule binders. ACS Medicinal Chemistry Letters. 2017

[131] Moreno L, Marshall LV, Pearson ADJ, Morland B, Elliott M, Campbell-Hewson Q, et al. A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: A cancer research UK study. Clinical Cancer Research. 2015

[132] Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. International Journal of Cancer. 2012

[133] Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, et al. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: Challenges to run early phase clinical trials for children with leukemia. Pediatric Blood & Cancer. 2017

[134] Foran JM, Ravandi F, O'Brien SM, Borthakur G, Rios M, Boone P, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. Journal of Clinical Oncology. 2008
[135] Dent S, Chi K, Jonker D, Capier K, Simpson R, Chen E, et al. 512 NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion. European Journal of Cancer Supplements. 2010

[136] Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, et al. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells. Leukemia & Lymphoma. 2013

[137] Duong JK, Griffin MJ, Hargrave D, Vormoor J, Edwards D, Boddy AV. A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. British Journal of Clinical Pharmacology. 2017

[138] Li Y, Tan C, Gao C, Zhang C, Luan X, Chen X, et al. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors. Bioorganic & Medicinal Chemistry. 2011

[139] Chu B, Liu F, Li L, Ding C, Chen K, Sun Q, et al. A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells. Cell Death & Disease. 2015

[140] Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007

[141] Han C, Wan L, Ji H, Ding K, Huang Z, Lai Y, et al. Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. European Journal of Medicinal Chemistry. 2014

[142] Determann R, Dreher J, Baumann K, Preu L, Jones PG, Totzke F, et al. 2-Anilino-4-(benzimidazol-2-yl)pyrimidines—A multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines. European Journal of Medicinal Chemistry. 2012

[143] Wang S, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, et al. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: Synthesis, SAR analysis, X-ray crystallography, and biological activity. Journal of Medicinal Chemistry. 2004

[144] Shao H, Shi S, Huang S, Hole AJ, Abbas AY, Baumli S, et al. Substituted 4-(thiazol-5-yl)-2-(phenylamino) pyrimidines are highly active CDK9 inhibitors: Synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. Journal of Medicinal Chemistry. 2013

[145] Wang S, Griffiths G, Midgley CA, Barnett AL, Cooper M, Grabarek J, et al. Discovery and characterization of 2-anilino-4-(thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chemistry & Biology. 2010

[146] McCoull W, Hennessy EJ, Blades K, Chuaqui C, Dowling JE, Ferguson AD, et al. Optimization of highly kinase selective bis-anilino pyrimidine PAK1 inhibitors. ACS Medicinal Chemistry Letters. 2016

[147] Gandin V, Ferrarese A, Dalla Via M, Marzano C, Chilin A, Marzaro G. Targeting kinases with anilinopyrimidines: Discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Scientific Reports. 2015

[148] Zhang Q, Liu Y, Gao F, Ding Q, Cho C, Hur W, et al. Discovery of EGFR selective 4,6-disubstituted pyrimidines
from a combinatorial kinase-directed heterocycle library. Journal of the American Chemical Society. 2006

[149] Von Ahren O, Bömer U. High-throughput screening for kinase inhibitors. Chembiochem. 2005

[150] Bistrović A, Krstulović L, Harej A, Grbčić P, Sedić M, Koštrun S, et al. Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer. European Journal of Medicinal Chemistry. 2018

[151] Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. Journal of Medicinal Chemistry. 2005

[152] Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. OncoTargets and Therapy. 2011